Filings Radar

SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.

CHAMPIONS ONCOLOGY, INC. (CSBR)

CIK 0000771856 2 material events

Insider activity (SEC Form 4)

Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.

Open-market · last 30 days: 0 buyers bought $0 0 sellers sold $0
Open-market · last 90 days: 0 buyers bought $0 0 sellers sold $0
InsiderRoleDateTransactionSharesValue
ACKERMAN JOEL Director 2025-10-30 Option exercise 94405 $198K
Most recent 1 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.

Risk Radar (year-over-year Risk Factors)

← All Risk Radar

Fiscal period ending 2026-04-30 versus 2025-04-30 — view filing on EDGAR →

Liquidity has deteriorated sharply — cash halved, operations swung to a loss, and burn accelerated — raising meaningful near-term runway risk. Compounding this, geopolitical exposure broadened with the explicit addition of Iran and its proxies to the conflict disclosure, while a CEO-to-Chairman leadership transition adds execution uncertainty. Neither change alone clears the going-concern bar, but together they represent a substantive worsening across two distinct risk dimensions.

1 company-specific · 1 common-mode

Company-specific changes

Revised

Cash balance halved ($9.8M to $4.9M), swung to operating loss ($4.7M income to $1.2M loss), and cash burn accelerated. Liquidity runway materially tightened.

We historically incurred losses from operating activities, may require significant capital and may never achieve sustained profitability. For the fiscal year ended April 30, 2026, the Company had a…

Also disclosed — common-mode (Geopolitical macro uncertainty)
Geopolitical macro uncertainty Revised

Leadership role changed from CEO to Chairman; conflict scope expanded from "ongoing war" to "ongoing wars with Iran and its proxies," escalating geopolitical risk.

Our Chairman of the Board of Directors resides in Israel and we have several customers with their operations located in Israel, and, therefore, our leadership continuity and results may be adversely…

Material year-over-year changes to this company's Risk Factors (Item 1A), found by comparing each annual report to the prior year, judged for materiality, and classified as company-specific or common-mode against the cross-company catalog. Common-mode changes are the macro themes many companies disclose in common; they are collapsed above. A filing marked unchanged had no material change from the prior year; its summary describes the company's standing risks, which remain in force. Fiscal periods are the reporting period ends. Not investment advice.

Earnings release

8-K filed 2026-09-10 confidence 98% Item 2.02

Champions Oncology issued a press release on September 10, 2026 disclosing unaudited financial results for its first quarter ended July 31, 2026. The disclosure includes revenue of $15.2 million (8.8% YoY growth), oncology services margin improvement to 51%, adjusted EBITDA of $671,000, and a net loss of $426,000. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.

View raw filing on EDGAR →

Earnings release

8-K filed 2026-07-27 confidence 98% Item 2.02

Champions Oncology issued a press release on July 27, 2026 disclosing audited financial results for fiscal year ended April 30, 2026, including record annual revenue of $59.4 million, fourth consecutive quarter of positive adjusted EBITDA, and detailed quarterly and year-to-date financial performance. This is a standard earnings release disclosure under Item 2.02 with the press release attached as Exhibit 99.1.

View raw filing on EDGAR →